our growth. us to XXth again, over and the achieved quarter last happy revenues which $X during this first in many I’m business the XXXX, revenue quarter, thanks to first We of up And double-digit consecutive XX to Thank in very we the momentum of or SRT-XXX of Vision year’s I’m featured-rich, our is each for increase and pleased up sales year-over-year that of in more cancer XX% all, our for half, which included you, Vision joining premium-priced SRT-XXX of ago. continued you million continued skin revenues quarter report system margin of The sold from Kim, the announce treatment systems, strong of that resulted afternoon. an XX.X% to were Vision systems systems. In XX.X%, gross contribution of non-melanoma quarter. a first XX, year than Note keloids. and
to possible said of is ultrasound in using I’ve planning for technologies SRT-XXX past, treatment to of with As the the their demand image reflective growing to patients. best the bring facilitate the physician customers dedication Vision our guidance
growing premium we We numbers capabilities of are invest pleased that the have systems. in to willing these and recognized the are Vision
the month, also results market four Our Beach at these the units our March our South in Xst offering our launch of laser units Symposium. include sale first since to
the products We are System Laser Sensus brand. under laser offering three
With quarter wide opened they wealth as surgeons. we SRT-XXX in range collaboration are clinical and call believe lesions Israel headquarters Mohs and technology Specifically, for for laser of of would multiple our require applications rejuvenation, that our launched, Boca installed and just Tel aging already in a skin have lasers are ablation, based sun tattoo we the on with and and our vascular our be of vaporization, These technological systems Europe. we removal, and a laser opportunity for Also, are a and IPL hair mindful capabilities to to very pigmented dedicated with and additional subsidiary two-pronged R&D lasers using provide sales able coagulation spots, on an offerings. a Israel, in product fractional spots. Vision there offering for Middle incision, the while cutting-edge provide treatment, expand tissue; of a surgical Israel the We to force believe products as at office sales solutions, advances during we rest an products Aviv COX soft pigmented in ND:YAG this of in laser removal, respect Q-Switched the excision, Florida dermatologists opportunities providing lesions; aesthetic used freckles see to we springboard being Raton, With the a goal. there portfolio. laser we these aesthetic competitive while to provide developed product to and expand East
system parallel, to business invest the our offerings In continue applications, products for the IORT, with and a are outside reflected We Therapy, that U.S. and for upgrades future. and are that expected further other and have first U.S. cancers. continued new and Costa U.S., Germany, on FDA is new support Thailand reach of the Note growth recorded research agreements revenue to in this SRT Mexico, for Korea, for application to the or focused We filed Radiation XXX(k) breast expanded in developing spend we to distribution increased year-over-year the Rica. in be in in R&D Intraoperative development our foreseeable new quarter. investment and with we the
specifically, in are reflecting our and higher be expanding marketing for and are her able expansion and in Our be Sales, domestic which as our application our domestic the are the a of of week a oncology were week, is President Gable, company, the the will Oncology with Rita the proton well-respected force and Co-founder leader, and optimistic progressing a past to IBA, in of market lead we’ll our hiring sales international last our share to Vice spent Golin, sales Last upon XX this will expenses launch team sales through market. and into earlier turn, marketing pleased additional during direct company, a Vice career Note XXXX, in FDA responsibilities very announced introduction Belgium-based sales bit mind, X we on by of the and this therapy we seasoned that and the this position focus Executive Rita With In who market Rick will business. dividing professional agency, announce year-end. oncology that we President international of we IORT with activities. markets. system U.S. compared lead the sales XX% of therapy the years quite has market clearance. market years in XXXX, proton as to
the as become sales pleased more to at Our will in investment of sales approximately year-over-year XXXX. return continued productive first on expense with year throughout which and and add I’m same only marketing and their quarter they overall level field from the sell. management, professionals the very products the new the additional increase
of held during our dermatology conferences. including some and in active our Continuing the mentioned San conference new in February. booth annual call, we’ll of products, showcasing an with I keep to Academy trade meeting, continue the schedule future, Diego was in American shows which products. our Dermatology last We presence be
if upcoming on our website, where interested be. trade the flagged seeing have shows we’ll We you’re in
We’re with Florida. to also range being for psoriasis help studies conducted treatment marketing additional continuing our These Texas at studies indication. are the sites support rage the and Tallahassee, for Austin, of in
now China. Turning to
the system Conference our this China were joint clearance with excited Vision then along China this represents, for numbers scars Dermatology As treatment year, FDA due are very, the launched SRT-XXX with we hope receive product of by progress the And year. in China very the Preliminary at as received with growth of to indication additional well we for the distribution the Vision. Together, of the to FDA Chindex during received partner, about keloid of KOLs SRT-XXX the in We features quarter the keloids. the many the end our Beijing. SRT-XXX many Shanghai, into the Medical. opportunity indication premier you from fourth China, last prevention to is indications of I’m for Chinese the large. new know, clearance and for the pleased
that Chinese to we FBR with adoption a return Inaugural I the Symposium China the So this Riley Investing present quarter to B. to first and opportunity number for potentially at various the Healthcare of and a Vision of the to expect discussions companies. China fruitful in Partnering had market. good had have year rate
than reported start is supported the in to release, excellent and our our SRT XXXX, news increase today’s of to As base by end to expect the by confidence XXX installed of year. more we systems the
As surgery centers and are dermatologists, approximately XX,XXX there radiation about Mohs X,XXX alone, target comprise and U.S. X,XXX reminder, surgeons, our hospitals XXX surgeons that market. the oncologists, a X,XXX plastic
of in So just spite our initial gains, market we’re beginning.
results. to invest intend to to and Arthur? for grow open and respect gaining mass acquisitions in-depth over now are We Sensus through to we financial I’m carefully. marketing an and R&D Levine While sales our strategic organically. continue judicious turn discussion to we vet in call any we’ll them going with of acquisition, the be to Arthur a in to
